Aisimai
Latest round
- Series A
Last raised
- Mar 2020
Total raised
- $0.7M
Investors
- 6
About Aisimai
Established in 2016 and based in Guangzhou, China, Aisimai is a biomedical developer that focuses on bispecific antibody drugs. Dr. Wenjun Zhang, the CEO of the company, once served as the R&D staff of Novartis and MacroGenics. More than 20% of the core research team has master's degree. The company cooperates with Zhenge Biotech, OPM and Joinn. The company provides dual-targeted antibody drugs for tumor treatment field, such as gastric cancer, breast cancer and rheumatoid arthritis. The product of the company includes EX103 and EX101. The company adopts antibody discovery and verification platform and bispecific antibody platform ExMab®, including antibody engineering construction and screening and clinical medication. The company will increase the investment of developing new products and declare investigational new drug(IND).
Who invested in Aisimai
6 investors across 2 rounds
See all investors in Aisimai
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aisimai
Who invested in Aisimai?
Aisimai has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aisimai raised?
Aisimai has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Aisimai last raise money?
Aisimai's most recent round on record is a Series A, in Mar 2020.
What does Aisimai do?
Established in 2016 and based in Guangzhou, China, Aisimai is a biomedical developer that focuses on bispecific antibody drugs.
Where is Aisimai headquartered?
Aisimai is headquartered in Guangzhou, China.
Which VCs invest in companies like Aisimai?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Aisimai's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Aisimai? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.